Despite this political clout, the company also tried to belay its image as a pharma monster ... creating a combined company called Viatris. The $12 billion deal was cleared in November 2020 ...

A spokesperson for Viatris, marketing authorisation holder and distributor of Creon in the UK, said: “We were notified by our ...

Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of ...

As Leo stands in his office, overseeing the entrance of Viatris' bustling office in the Netherlands, he reflects on the 50 years that have shaped his journey with the company. From his early days ...

Viatris VTRS, a global healthcare company, is scheduled to report fourth-quarter and full-year 2024 results on Feb. 27, 2025.

Viatris Inc. (VTRS), headquartered in Canonsburg, Pennsylvania, is a leading global healthcare company dedicated to empowering people worldwide to live healthier at every stage of life. With a ...

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

LONDON, Feb 21 (Reuters) - The U.S. government's foreign aid freeze has upended the supply chain for medical products crucial for fighting diseases including HIV and malaria in some of the world's ...

Zooming in further, Viatris has lagged behind the SPDR S&P Pharmaceuticals ETF’s 6.3% gains over the past 52 weeks and 4.8% return in 2025. On Nov. 7, Viatris announced its third-quarter ...

Open to individuals, startups, and institutions worldwide, the ADGHW Innovation Award recognises innovations that enhance ...

Apart from Viatris, previously Mylan, there is no leading US player in the generics space. Also read | Has your medical device been tested by a qualified officer or a pharmacist? The regulator ...